Analysts Set Doximity, Inc. (NYSE:DOCS) Price Target at $32.18

Shares of Doximity, Inc. (NYSE:DOCS) have been assigned an average rating of “Hold” from the twenty-five research firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $32.1818.

Several brokerages have weighed in on DOCS. Wolfe Research raised Doximity to an “outperform” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. raised their price objective on Doximity from $26.00 to $31.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Doximity in a research note on Friday, August 7th. Wells Fargo & Company cut Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price for the company. in a report on Monday, August 10th. Finally, Canaccord Genuity Group set a $36.00 target price on Doximity in a research report on Friday, August 7th.

Doximity Stock Up 0.1%

Doximity stock opened at $26.52 on Thursday. Doximity has a 52-week low of $17.15 and a 52-week high of $76.51. The firm’s fifty day moving average is $24.35 and its 200 day moving average is $23.14. The company has a market cap of $4.73 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 20.73 and a beta of 1.25.

Doximity (NYSE:DOCS) last posted its earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.36 earnings per share. On average, equities research analysts anticipate that Doximity will post 0.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Doximity news, CAO Siddharth Sitaram sold 2,077 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $26.02, for a total transaction of $54,043.54. Following the transaction, the chief accounting officer owned 96,045 shares in the company, valued at $2,499,090.90. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Wampler sold 2,000 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $24.95, for a total transaction of $49,900.00. Following the completion of the sale, the director directly owned 19,839 shares in the company, valued at approximately $494,983.05. This represents a 9.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,347 shares of company stock valued at $441,412 over the last three months. 31.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Doximity

Several hedge funds have recently added to or reduced their stakes in DOCS. Lifestyle Asset Management Inc. raised its position in Doximity by 5.9% during the 4th quarter. Lifestyle Asset Management Inc. now owns 7,083 shares of the company’s stock worth $314,000 after buying an additional 396 shares during the last quarter. Fielder Capital Group LLC increased its stake in shares of Doximity by 12.0% during the fourth quarter. Fielder Capital Group LLC now owns 5,844 shares of the company’s stock worth $259,000 after acquiring an additional 628 shares during the period. Legato Capital Management LLC increased its stake in shares of Doximity by 15.4% during the fourth quarter. Legato Capital Management LLC now owns 5,397 shares of the company’s stock worth $239,000 after acquiring an additional 722 shares during the period. Leonteq Securities AG raised its holdings in Doximity by 65.6% during the first quarter. Leonteq Securities AG now owns 2,912 shares of the company’s stock worth $68,000 after purchasing an additional 1,154 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its holdings in Doximity by 6.4% during the first quarter. Pictet Asset Management Holding SA now owns 19,224 shares of the company’s stock worth $448,000 after purchasing an additional 1,156 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity was named a founding partner in Fireworks’ Specialized Intelligence Index and launched “Bedside Bench,” an open-source benchmark designed to evaluate clinical-grade AI. The initiative could strengthen Doximity’s positioning in healthcare AI and create longer-term product and brand opportunities. Doximity Named Leading Clinical AI Benchmark in Fireworks’ Cross-Industry Index
• Neutral Sentiment: Several reports highlighted Doximity’s AI benchmark launch and its recognition as a leading clinical AI benchmark. While the announcements may improve visibility, they do not provide near-term revenue or earnings guidance.
• Negative Sentiment: Multiple law firms announced or promoted a securities-fraud class action involving investors who purchased DOCS shares from August 8, 2024, through May 13, 2026. The allegations claim Doximity overstated Newsfeed engagement and growth while failing to disclose market-share erosion, competitive pressures, and advertising practices; the claims have not been proven in court. Doximity Securities Litigation Announcement
• Negative Sentiment: Investors have until November 16, 2026 to seek appointment as lead plaintiff. The unusually high volume of law-firm notices increases headline risk and could weigh on DOCS even as the shares have recently traded above their longer-term moving averages. Doximity Lead Plaintiff Deadline

About Doximity

Doximity, Inc operates a digital platform for U.S. medical professionals. Its network enables physicians and other healthcare providers to communicate, collaborate, access medical news and research, maintain professional profiles, and connect with colleagues and patients.

The company offers a range of tools for healthcare organizations and professionals, including telehealth services, digital faxing, scheduling and communication products, and solutions for recruiting and marketing. Doximity also provides pharmaceutical and healthcare companies with digital engagement services designed to reach medical professionals through its platform.

Founded in 2010, Doximity is headquartered in San Francisco and primarily serves the United States healthcare market.